Skip to Content

Notice

Controlled Substances: 2000 Aggregate Production Quotas

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Drug Enforcement Administration (DEA), Justice.

ACTION:

Notice of final 2000 aggregate production quotas.

SUMMARY:

This notice establishes final 2000 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA). The DEA has taken into consideration comments received in response to a notice of the proposed revised aggregate production quotas for 2000 published July 19, 2000 (65 FR 44836).

EFFECTIVE DATE:

September 25, 2000.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On July 19, 2000, a notice of the proposed revised 2000 aggregate production quotas for certain controlled substances in Schedules I and II was published in the Federal Register (65 FR 44836). All interested parties were invited to comment on or object to these proposed aggregate production quotas on or before August 18, 2000.

Several companies and one individual commented that the revised aggregate production quotas for amphetamine, codeine (for sale), dextropropoxyphene, dihydrocodeine, hydrocodone (for sale), hydromorphone, meperidine, methadone intermediate, methylphenidate, opium, oxycodone (for sale), oxycodone (for conversion), oxymorphone, pentobarbital, phenylacetone, and tetrahydrocannabinols were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

DEA has taken into consideration the above comments along with the relevant 1999 year-end inventories, initial 2000 manufacturing quotas, 2000 export requirements, and actual and projected 2000 sales. Based on this information, the DEA has adjusted the final 2000 aggregate production quotas for 4-methoyxamphetamine, amphetamine, dihydrocodeine, hydromorphone, meperidine, methamphetamine, oxycodone (for sale), oxycodone (for conversion), oxymorphone and pentobarbital to meet the legitimate needs of the United States.

Regarding codeine (for sale), dextropropoxyphene, hydrocodone (for sale), methadone intermediate, opium, methylphenidate, phenylacetone and tetrahydrocannabinols, the DEA has determined that no adjustments of the aggregate production quotas are necessary to meet the 2000 estimated medical, scientific, research and industrial needs of the United States.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby orders that the final 2000 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic classEstablished final 2000 quotas
Schedule I:
2,5-Dimethoxyamphetamine10,501,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)2
3-Methylfentanyl14
3-Methylthiofentanyl2
3,4-Methylenedioxyamphetamine (MDA)20
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)30
3,4-Methylenedioxymethamphetamine (MDMA)20
3,4,5-Trimethoxyamphetamine2
4-Bromo-2,5-Dimethoxyamphetamine (DOB)2
4-Bromo-2,5-Dimethoxyphenethylamine (2 CB)2
4-Methoxyamphetamine251,000
4-Methylaminorex3
4-Methyl-2,5-Dimethoxyamphetamine (DOM)2
5-Methoxy-3,4-Methylenedioxyamphetamine2
Acetyl-alpha-methylfentanyl2
Acetyldihydrocodeine2
Acetylmethadol7
Allylprodine2
Alphacetylmethadol7
Alpha-ethyltryptamine2
Start Printed Page 57625
Alphameprodine2
Alphamethadol2
Alpha-methylfentanyl2
Alpha-methylthiofentanyl2
Aminorex7
Benzylmorphine2
Betacetylmethadol2
Beta-hydroxy-3-methylfentanyl2
Beta-hydroxyfentanyl2
Betameprodine2
Betamethadol2
Betaprodine2
Bufotenine2
Cathinone9
Codeine-N-oxide2
Diethyltryptamine2
Difenoxin10,000
Dihydromorphine508,000
Dimethyltryptamine3
Gamma-hydroxybutyric acid15,000,000
Heroin2
Hydroxypethidine2
Lysergic acid diethylamide (LSD)63
Mescaline7
Methaqualone17
Methcathinone9
Morphine-N-oxide2
N,N-Dimethylamphetamine7
N-Ethyl-1-Phenylcyclohexylamine (PCE)5
N-Ethylamphetamine7
N-Hydroxy-3,4-Methylenedioxyamphetamine2
Noracymethadol2
Norlevorphanol2
Normethadone7
Normorphine7
Para-fluorofentanyl2
Pholcodine2
Propiram415,000
Psilocybin2
Psilocyn2
Tetrahydrocannabinols115,000
Thiofentanyl2
Trimeperidine2
Schedule II:
1-Phenylcyclohexylamine12
1-Piperidinocyclohexanecarbonitrile (PCC)10
Alfentanil8,000
Alphaprodine2
Amobarbital12
Amphetamine10,958,000
Cocaine251,000
Codeine (for sale)43,248,000
Codeine (for conversion)52,384,000
Dextropropoxyphene121,017,000
Dihydrocodeine244,000
Diphenoxylate931,000
Ecgonine36,000
Ethylmorphine12
Fentanyl300,000
Glutethimide2
Hydrocodone (for sale)21,417,000
Hydrocodone (for conversion)20,700,000
Hydromorphone1,409,000
Isomethadone12
Levo-alphacetylmethadol (LAAM)12
Levomethorphan2
Levorphanol27,000
Meperidine10,168,000
Metazocine1
Methadone (for sale)8,347,000
Methadone (for conversion)0
Methadone Intermediate9,503,000
Start Printed Page 57626
Methamphetamine2,104,000
850,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,225,000 grams for methamphetamine for conversion to a Schedule III product; and, 29,000 grams for methamphetamine (for sale)
Methylphenidate14,957,000
Morphine (for sale)14,706,000
Morphine (for conversion)97,410,000
Nabilone2
Noroxymorphone (for sale)25,000
Noroxymorphone (for conversion)3,813,000
Opium720,000
Oxycodone (for sale)35,850,000
Oxycodone (for conversion)602,000
Oxymorphone353,000
Pentobarbital24,037,000
Phencyclidine41
Phenmetrazine2
Phenylacetone10
Secobarbital22
Sufentanil1,700
Thebaine45,444,000

The Deputy Administrator further orders that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 13132, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Start Signature

Dated: September 15, 2000.

Julio F. Mercado,

Deputy Administrator.

End Signature End Supplemental Information

[FR Doc. 00-24554 Filed 9-22-00; 8:45 am]

BILLING CODE 4410-09-M